Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P.

PLoS Med. 2004 Oct;1(1):e19. Epub 2004 Oct 19. Erratum in: PLoS Med. 2004 Dec;1(3):e73.

2.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

3.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 10;12 :CD004246.

PMID:
21154355
4.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
5.

Impact of nevirapine on lipid metabolism.

Clotet B, van der Valk M, Negredo E, Reiss P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S79-84. Review.

PMID:
14562862
7.
8.

Clinical uses of non-nucleoside reverse transcriptase inhibitors.

Harris M, Montaner JS.

Rev Med Virol. 2000 Jul-Aug;10(4):217-29. Review.

PMID:
10891870
9.
10.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
11.

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.

Pillay P, Ford N, Shubber Z, Ferrand RA.

PLoS One. 2013 Jul 22;8(7):e68995. doi: 10.1371/journal.pone.0068995. Print 2013. Review.

12.

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.

Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, Hargreaves S, Mills EJ, Ford N.

AIDS. 2013 Jun 1;27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0. Review.

PMID:
23343913
13.

First-line antiretroviral therapy in Africa--how evidence-base are our recommendations?

Colebunders R, Kamya MR, Laurence J, Kambugu A, Byakwaga H, Mwebaze PS, Muganga AM, Katwere M, Katabira E.

AIDS Rev. 2005 Jul-Sep;7(3):148-54. Review.

PMID:
16302462
14.
15.

Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.

Bera E, Mia R.

S Afr Med J. 2012 Oct 8;102(11 Pt 1):855-9. doi: 10.7196/samj.5700. Review. Erratum in: S Afr Med J. 2012 Dec;102(12):898.

PMID:
23116743
16.

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.

Kontorinis N, Dieterich DT.

Semin Liver Dis. 2003 May;23(2):173-82. Review.

PMID:
12800070
17.

Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.

Souza SJ, Luzia LA, Santos SS, Rondó PH.

Rev Assoc Med Bras (1992). 2013 Mar-Apr;59(2):186-98. doi: 10.1016/j.ramb.2012.11.003. Review.

18.

Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.

Patel RC, Onono M, Gandhi M, Blat C, Hagey J, Shade SB, Vittinghoff E, Bukusi EA, Newmann SJ, Cohen CR.

Lancet HIV. 2015 Nov;2(11):e474-82. doi: 10.1016/S2352-3018(15)00184-8. Epub 2015 Oct 22. Review.

19.

Neuropsychiatric side effects of efavirenz therapy.

Arendt G, de Nocker D, von Giesen HJ, Nolting T.

Expert Opin Drug Saf. 2007 Mar;6(2):147-54. Review.

PMID:
17367260
20.

Supplemental Content

Support Center